Malaysia Gastroesophageal Reflux Disease (GERD) Drugs Market Analysis

Malaysia Gastroesophageal Reflux Disease (GERD) Drugs Market Analysis


$ 3999

Malaysia Gastroesophageal Reflux Disease (GERD) Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The high prevalence of GERD, rising awareness and diagnostic rates, technology improvements, and lifestyle variables are all driving factors in the Gastroesophageal Reflux Disease (GERD) medications market. Some prominent global players in the Gastroesophageal Reflux Disease (GERD) drugs market include AstraZeneca PLC, Pfizer Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Company, AbbVie Inc., Mylan N.V., Perrigo Company plc, and Sun Pharmaceutical Industries Ltd.

ID: IN10MYPH282 CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Vidhi Upadhyay

Buy Now

Malaysia Gastroesophageal Reflux Disease (GERD) Drugs Market Analysis Summary

Malaysia Gastroesophageal Reflux Disease (GERD) Drugs Market is valued at around $8.9 Mn in 2022 and is projected to reach $10.5 Mn by 2030, exhibiting a CAGR of 2.18% during the forecast period 2023-2030.

Gastroesophageal reflux disease (GERD) is a condition that develops when there is a retrograde flow of stomach contents back into the esophagus. The incidence of GERD is high in the general population, it is estimated to affect up to 20% of the population worldwide. Western countries and the USA have GERD prevalence higher than Asia; it ranges from 10 to 30% and more. Drivers of the Gastroesophageal Reflux Disease (GERD) drugs market include the high prevalence of GERD, growing awareness and diagnosis rates, technological advancements, and lifestyle factors. Some prominent global players in the Gastroesophageal Reflux Disease (GERD) drugs market include AstraZeneca PLC, Pfizer Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Company, AbbVie Inc., Mylan N.V., Perrigo Company plc, and Sun Pharmaceutical Industries Ltd.

Market Dynamics

Market Growth Drivers

  1. Rising GERD Prevalence: The rising global prevalence of GERD is a major market driver. Obesity and poor eating habits, for example, contribute to an increase in GERD cases, resulting in a greater requirement for drugs
  2. Rising Knowledge and Diagnosis: Greater awareness of GERD symptoms, combined with improved diagnostic tools, has resulted in a greater diagnosis rate. As more persons are diagnosed with GERD, there is a greater need for effective medications to treat the problem
  3. Lifestyle Changes and Dietary Habits: Lifestyle modifications, including dietary changes, weight management, and avoiding trigger foods, are often recommended as the first line of treatment for GERD. However, when lifestyle changes are not sufficient, medications become necessary, driving the demand for GERD drugs
  4. Technological Advances in Drug Development: Technological advances in pharmaceutical research and development have resulted in the release of new and more effective GERD medications. Proton pump inhibitors (PPIs), for example, have improved the therapy choices available to GERD sufferers

Market Restraints

  1. Side Effects and Safety Concerns: GERD drugs, particularly long-term use of PPIs, can be associated with certain side effects and safety concerns. These include risks of bone fractures, kidney problems, and potential drug interactions. Safety concerns can affect patient compliance and limit the use of medications
  2. Generic Competition: Several GERD drugs have lost or are approaching the expiration of their patent protection, leading to increased generic competition. The availability of lower-cost generic alternatives can impact the market growth of branded GERD drugs
  3. Preference for Non-pharmacological Approaches: Some patients may prefer non-pharmacological approaches, such as lifestyle modifications, dietary changes, and alternative therapies, to manage GERD. This preference can limit the market growth of GERD drugs, especially in milder cases where medications may be less necessary

Competitive Landscape

Key Players

  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • AbbVie Inc.
  • Mylan N.V.
  • Perrigo Company plc
  • Sun Pharmaceutical Industries Ltd.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Malaysia Gastroesophageal Reflux Disease (GERD) Drugs Market Segmentation

By Drug Class

  • Proton Pump Inhibitors (PPIs)
  • Histamine-2 Receptor Antagonists (H2RAs)
  • Antacids
  • Prokinetic Agents

By Route of Administration

  • Oral Drugs
  • Injectable Drugs

By Age

  • Adult
  • Pediatric

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Riya Doshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up